Illumina collaborated on a study presented at ASCO 2025 showing that circulating tumor DNA provides actionable data for clinical trials
Illumina bioinformatics solutions prove essential for a Northern Territory genomics program
At ESHG 2025 in Milan, Illumina welcomed customers and industry colleagues to discuss the future of genomic research and health care
NYU Langone Director of Molecular Pathology Matija Snuderl says every brain cancer journey should begin with DNA methylation profiling
Date | Publication | Title |
---|---|---|
2 Jun. 2025 | Pharma Outlook | The Future of Genomic Sequencing: Trends That Will Define the Next Decade |
29 May 2025 | Medical Device Network | Illumina widens access to cancer tests with Medicare and new CDx |
29 May 2025 | GenomeWeb | ESHG: Studies Demonstrate Potential of Long-Read Sequencing in Rare Disease Diagnostics |
29 May 2025 | Endpoints News | DNA giant Illumina spawned an ecosystem of competitors and customers |
28 May 2025 | CAP Today | NGS and the cancer biomarker balancing act |
At Illumina, we push boundaries. We think beyond the conventional. We dream big. With the energy of so many bright and accomplished people, the opportunities are endless.
Search for JobsIf you are a member of the media:
If you are not a member of the media, please visit Contact Us.